NFKB1 and cancer: The significantly enriched gene signatures in mice treated with the cancer therapeutics (oxaliplatin and PD-1 blockade) and B. bre JCM92 compared to mice treated with cancer therapeutics and B. bre Bb03 included gene sets involving E2F targets, tumor necrosis factor-α (TNF-α) signaling via nuclear factor kappa B (NFκB), allograft rejection, and inflammatory response (Figure 6E and Figure S1).